Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8420771 | 1.00 | NPC1 (0.67) | NPC1RAB9ALMNATAAR1ESR1 | |
| SCHEMBL6679690 | 1.00 | NPC1 (0.67) | NPC1RAB9ALMNATAAR1ESR1 | |
| SCHEMBL13623898 | 0.89 | NPC1 (0.65) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL31545476 | 0.87 | NPC1 (0.63) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL8986825 | 0.85 | ESR1 (0.54) | NPC1RAB9ATAAR1ESR1KCNH2 | |
| SCHEMBL11959175 | 0.85 | ACACB (0.56) | NPC1RAB9ALMNAESR1KCNH2 | |
| SCHEMBL8986819 | 0.85 | ESR1 (0.54) | NPC1RAB9ATAAR1ESR1KCNH2 | |
| SCHEMBL9180602 | 0.84 | FOLH1 (0.52) | NPC1RAB9AESR1KCNH2ALDH1A1 | |
| SCHEMBL9183694 | 0.84 | NPC1 (0.63) | NPC1RAB9ALMNATAAR1KMT2A | |
| SCHEMBL6540778 | 0.84 | CYP1A2 (0.51) | NPC1RAB9AESR1KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| US-4016146-A | Phenethylamine antigenic conjugates, their preparation, antibodies, and use | BIOLOGICAL DEVELOPMENTS, INC. (US) | 1977-04-05 | — | — | US | disclosed |
| US-3996344-A | Phenethylamine antigenic conjugates, their preparation, antibodies and use | BIOLOGICAL DEVELOPMENTS, INC. (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | NPC1 1806/4885RAB9A 766/4885LMNA 4698/4885 |
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | NPC1 4399/4885RAB9A 1893/4885LMNA 3736/4885 |
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | NPC1 4691/4885RAB9A 1763/4885LMNA 3590/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | NPC1 4587/4885RAB9A 2688/4885LMNA 4565/4885 |
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | NPC1 4528/4885RAB9A 1610/4885LMNA 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.